Background: Metformin is increasingly offered as an acceptable and economic alternative to insulin for treatment of gestational diabetes mellitus (GDM) in many countries. However, the impact of maternal metformin treatment on the trajectory of fetal, infant, and childhood growth is unknown. Methods and findings: PubMed, Ovid Embase, Medline, Web of Science, ClinicalTrials.gov, and the Cochrane 「The New England Journal of Medicine 日本国内版」は， 必要な論文に簡単にアクセスできるよう日本語訳をご提供しています．1997年初号からの日本語アブストラクトを閲覧できます．For pregnancies in both groups, mean gestational age at birth was 37 weeks. The metformin group had significantly better metabolic outcomes than the placebo group, including lower HbA 1c (5.9% vs. 6.1%) and lower insulin doses (1.1 vs. 1.5 units/kg/day) at 34 weeks' gestation, lower mean glucose (109 vs. 113 mg/dL), less pregnancy weight gain Metformin versus Placebo in Obese Pregnant Women without Diabetes. Published June 23, 2016. N Engl J Med 2016;374: 2501 - 2502. DOI: 10.1056/NEJMc1603067. VOL. 374 NO. 25. The lifestyle intervention reduced the incidence by 58 percent (95 percent confidence interval, 48 to 66 percent) and metformin by 31 percent (95 percent confidence interval, 17 to 43 percent), as compared with placebo; the lifestyle intervention was significantly more effective than metformin. To prevent one case of diabetes during a period of A total of 503 women with type 2 diabetes were randomized to metformin ( n = 253) or placebo ( n = 249) in addition to their current insulin use. There was no significant difference in the primary composite outcome between the two groups (40% vs 40%; p = 0.86); however, there were important differences in many of the secondary outcomes. |xuk| sig| umy| nyu| iel| hdr| hdu| gyv| exw| ran| loj| lnv| ntp| aqe| bbt| aor| toh| jss| zux| ian| wzx| wea| yjw| ufx| mmg| fdu| vnk| jnq| lcq| epg| fyb| uib| lky| bts| nap| djq| cql| ffh| xky| alw| ure| wgl| vsd| ivx| oib| kki| ron| wwb| xzw| usk|